Phase 1 Trial of RTX-240, allogeneic red blood cells engineered to express 4-1BBL and trans-presented IL-15, in patients (Pts) with advanced solid tumorsOmid Hamid,Melissa L. Johnson, Jason Luke,Richard T. Maziarz, Jamie Merchan,Emerson E. Lim,Sandip P. Patel,Geoffrey M. Kuesters,Iga Sienczylo,Gilad Gordon,Karen Campbell, Kristin Horton,Laurence Turka,Alexander I. SpiraCANCER RESEARCH（2022）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
